BioCentury | Apr 21, 2008
Strategy

Celgene pipeline

Celgene pipeline Compound Description Indication Status From Orplatna satraplatin [partner: GPC] Oral platinum compound 2nd line hormone-refractory prostate cancer (HRPC) Under review in EU Pharmion Amrubicin Third-generation synthetic anthracycline Small cell lung cancer (SCLC) Ph...
BioCentury | Apr 21, 2008
Strategy

Celgene's 2020 foresight

Over the last few months, Celgene Corp. has spent some $3 billion to expand its pipeline of hematology/oncology products via one large acquisition and a series of three collaborations. The goal is to keep its...
Items per page:
1 - 2 of 2